These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34018630)

  • 1. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia.
    Palmer AJ; Campbell JA; de Graaff B; Devlin N; Ahmad H; Clarke PM; Chen M; Si L
    Health Econ; 2021 Aug; 30(8):1950-1977. PubMed ID: 34018630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.
    Kularatna S; Senanayake S; Gunawardena N; Graves N
    BMJ Open; 2019 Feb; 9(2):e024854. PubMed ID: 30772857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unchained melody: revisiting the estimation of SF-6D values.
    Craig BM
    Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the Functional Independence Measure to a multi-attribute utility instrument for economic evaluations in rehabilitation: a secondary analysis of randomized controlled trial data.
    Peiris CL; Taylor NF; Watts JJ; Shields N; Brusco NK; Mortimer D
    Disabil Rehabil; 2020 Oct; 42(21):3024-3032. PubMed ID: 30907143
    [No Abstract]   [Full Text] [Related]  

  • 7. Modeled cost-effectiveness of transforaminal lumbar interbody fusion compared with posterolateral fusion for spondylolisthesis using N(2)QOD data.
    Carreon LY; Glassman SD; Ghogawala Z; Mummaneni PV; McGirt MJ; Asher AL
    J Neurosurg Spine; 2016 Jun; 24(6):916-21. PubMed ID: 26895529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
    van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
    Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.
    Kennedy-Martin M; Slaap B; Herdman M; van Reenen M; Kennedy-Martin T; Greiner W; Busschbach J; Boye KS
    Eur J Health Econ; 2020 Nov; 21(8):1245-1257. PubMed ID: 32514643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions.
    Davis JC; Liu-Ambrose T; Khan KM; Robertson MC; Marra CA
    Osteoporos Int; 2012 Jul; 23(7):1849-57. PubMed ID: 21909728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the psychometric properties of the EQ-5D-3L and SF-6D in the general population of Chengdu city in China.
    Zhao L; Liu X; Liu D; He Y; Liu Z; Li N
    Medicine (Baltimore); 2019 Mar; 98(11):e14719. PubMed ID: 30882636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
    Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
    Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).
    Hawton A; Green C; Goodwin E; Harrower T
    Eur J Health Econ; 2019 Dec; 20(9):1335-1347. PubMed ID: 31410669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets.
    Poteet S; Craig BM
    Patient; 2021 May; 14(3):339-345. PubMed ID: 33782840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
    Adams R; Walsh C; Veale D; Bresnihan B; FitzGerald O; Barry M
    Pharmacoeconomics; 2010; 28(6):477-87. PubMed ID: 20465316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA.
    Falk Hvidberg M; Hernández Alava M
    Pharmacoeconomics; 2023 Oct; 41(10):1287-1388. PubMed ID: 37330973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study.
    Pickles K; Lancsar E; Seymour J; Parkin D; Donaldson C; Carter SM
    Soc Sci Med; 2019 Nov; 240():112560. PubMed ID: 31563007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.
    Shiroiwa T; Fukuda T; Ikeda S; Igarashi A; Noto S; Saito S; Shimozuma K
    Qual Life Res; 2016 Mar; 25(3):707-19. PubMed ID: 26303761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.